Committed to improving patient outcomes through reliable, high-quality sterile medications.
At Olyx Pharma, we are committed to improving patient outcomes by ensuring reliable access to high-quality sterile medications, particularly during times of drug shortages and supply disruption.
We partner with hospitals and healthcare systems to deliver consistent, ready-to-use compounded sterile preparations, helping providers maintain continuity of care with confidence.
Olyx Pharma operates as an FDA-registered 503B outsourcing facility under Section 503B of the Federal Food, Drug, and Cosmetic Act. We compound sterile medications without patient-specific prescriptions, in accordance with current Good Manufacturing Practice (cGMP) requirements, and are subject to FDA inspection, oversight, and reporting standards.
This framework enables us to deliver standardized, scalable, and reliable sterile solutions to healthcare providers. All our preparations undergo rigorous testing by independent laboratories, evaluating potency, sterility, pyrogens, and stability.
FDA-Registered 503B Facility
"At Olyx Pharma, we view sterile compounding as a critical component of healthcare infrastructure — not just a supply function."
Through disciplined quality systems, regulatory alignment, and dependable production, we support healthcare providers in delivering safe, effective care — when and where it is needed most.
Quality and safety are fundamental to everything we do. Our operations integrate process control, facility standards, and rigorous testing to support the highest levels of sterility and reliability.